Scientific rigour that doesn't read like a package insert.
Educational and promotional content for professionals and patients, produced with the evidence up front and the craft intact.
Why this rarely works
Healthcare material tends to land at one of two extremes. Either it's rigorous and nobody reads it, because it reads like an expanded package insert. Or it's compelling and doesn't survive review, because getting there required saying too much.
The middle exists, and it isn't an average of the two: it's understanding what the evidence says and finding the way to tell it that doesn't exceed it. That requires the writer to understand the data, not copy it.
What's included
Materials for healthcare professionals
Visual aids, congress materials, field-force content and medical communications, with verified references.
Content for patients and caregivers
Educational, adherence and support-programme material, in accessible register and without promising outcomes.
Audiovisual and visual production
Video, motion, photography, scientific illustration, 3D and product and packaging renders.
Adaptation and localization
Global assets taken to local market. This isn't translation: claims, legal copy, units, references and sometimes the whole concept change.
Why us
Every asset goes through medical and regulatory validation before it ships, and that review sits inside the creative process rather than after it. That's why a concept that can't be supported gets dropped at the cheap stage, while it's still an idea and not finished artwork.
The audience shapes the asset before the design does
Healthcare professionals
They read the data in context: which population was studied, what it was compared against and which endpoint was measured. An asset that shows the result without that context doesn't save the reader time: it takes away their ability to assess it. Every statement carries a reference that can be opened and checked.
Patients and caregivers
They need to understand the condition, the treatment and what to expect from the process, in a register that doesn't require medical training. The material supports the relationship with the treating physician and doesn't replace it: no asset promises an outcome or suggests a decision that belongs in the consultation.
The general public
Disease awareness content informs about symptoms, diagnosis and the importance of seeing a doctor. When the product is prescription-only, what may be mentioned to the general public is set by each market's regulation, and that is confirmed before the concept is written.
The field force
Material for sales representatives has to work without improvisation. Whatever isn't in the approved asset doesn't get added in conversation, which is why the asset anticipates the usual questions instead of leaving them to each person's judgement.
How an asset is built from the evidence
The work starts with the source, not the idea. First comes the approved product information for the market where the asset will run and the scientific material behind it. That reading defines what can be stated, and only then does the search for how to tell it begin.
Every statement is anchored to its reference at the exact place that supports it: the table, the figure or the paragraph. The type of evidence is recorded too, because a study's primary endpoint doesn't carry the same weight as a subgroup analysis or one run after the study ended.
The creative concept is checked against that list before it moves to design. If the idea needs to say something the evidence doesn't support, the idea changes. It's the stage where dropping things costs least.
With the artwork finished, the asset goes through medical and regulatory review before it reaches the client's approval workflow, and every version is logged with what changed and why. Final approval always sits with the pharmaceutical company.
The most common mistakes in healthcare content
Rounding a figure to fit the layout
A range that becomes a single number, an "up to" that disappears, a population that gets dropped. Each cut looks minor, and together they change what the study says.
Presenting a subgroup as the main result
The result for part of the study population doesn't say the same thing as the study's primary objective. If it's shown, it's labelled as what it is.
Charts that exaggerate the difference
A truncated bar-chart axis, or a scale chosen to widen a gap, communicates more than the data supports, even when every number is correct.
Images that imply an outcome
A person who appears recovered, or a before-and-after scene, makes a claim even if the text doesn't. Images are reviewed with the same criteria as copy.
Using one asset for professionals and patients
Changing the design isn't enough. They are audiences with different needs and different rules, and the material is conceived separately from the concept on.
Questions we get
Do you use AI to produce?
Yes, and we declare it. We use it where it adds — variants, adaptations, fast iteration — and skip it where it subtracts. In healthcare there's one additional line we don't negotiate: no generated image depicts a clinical outcome, a real patient, or an identifiable professional.
Who validates the scientific references?
They're checked against the primary source and the approved labeling before the asset enters design. A reference you can't open and read doesn't make it in.
Can you adapt material that's already globally approved?
It's a large part of the work. The difficulty isn't language — it's that global approval doesn't equal local approval, and some claims hold in one market and not in another.
Can you produce content about a condition without mentioning a product?
Yes. Awareness and education content about a condition is a regular part of the work, especially for patients, caregivers and the general public. What it can and can't include is defined market by market, together with the company's regulatory team.
What about evidence that isn't in the approved information yet?
A promotional asset stays within the approved product information for the market where it runs. If newer evidence exists, the channel through which it can be shared is set by the company's medical and regulatory teams, not by the asset.
Do you write the scientific content, or does the client provide it?
Both. We work from the scientific material the company provides and the primary sources behind it. We develop the copy, and final approval always sits with the client.
The other services
regulatory compliance
Medical and legal validation of every asset, by market and by brand, built into production instead of bolted on at the end.
See the service → 02strategic consulting
Brand, audiences, channels and competitors, analysed inside the real regulatory frame of the product and the market it will run in.
See the service → 04omnichannel and engagement
Communication journeys for professionals and patients, coordinated across channels and measured end to end.
See the service → 05paid media and performance
Search, social and programmatic inside each platform's health policies, with no sensitive data ever entering a pixel.
See the service →